Drugs / sodium fusidate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05105035 | Jun 2022 → Oct 2023 | melioidosis | Arrevus Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02569541 | Dec 2015 → Oct 2017 | osteomyelitis | Arrevus Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02570490 | Nov 2015 → Nov 2016 | — | Arrevus Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05353374 | Jan → May 2021 | seborrheic keratosis, skin tag | Indonesia University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05641298 Comparator | Feb → Sep 2023 | cystic fibrosis | Aceragen | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Fusidate | “ARV-1801 is an oral dosage form and loading dose regimen of sodium fusidate.” NCT05105035 ↗ |
| Known as | ARV-1801 | “ARV-1801 is an oral dosage form and loading dose regimen of sodium fusidate.” NCT05105035 ↗ |
| Route | Oral | “1500 mg by mouth every 12 hours” NCT02569541 ↗ |